• +1-646-491-9876
    • +91-20-67278686

    Search

    RAC Alpha Serine/Threonine Protein Kinase-Pipeline Review H1 2017

    RAC Alpha Serine/Threonine Protein Kinase-Pipeline Review H1 2017

    • Report Code ID: RW0001834342
    • Category Pharmaceuticals
    • No. of Pages 71
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H1 2017

    Summary

    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity. It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF) , epidermal growth factor (EGF) , insulin and insulin-like growth factor I (IGF-I) .

    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 7, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Metastatic Colorectal Cancer, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor) , Anal Cancer, Congenital Vascular Malformation, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST) , Glioblastoma Multiforme (GBM) , Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Pancreatic Cancer, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease and Solid Tumor.

    The latest report RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H1 2017, outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
    - The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    Almac Discovery Ltd
    ArQule Inc
    AstraZeneca Plc
    Bayer AG
    Merck & Co Inc
    Novartis AG
    Rexahn Pharmaceuticals Inc
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
    ALM-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARQ-092 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-5363 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAY-1125976 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-2206 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-2206 + selumetinib sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RX-0201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RX-0201N - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Akt1/2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit FAK, PKC alpha and AKT-1 for Breast Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trametinib dimethyl sulfoxide + uprosertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    uprosertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
    RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
    Featured News & Press Releases
    Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
    Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting
    Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting
    Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data For Archexin-Nano At The 2016 American Association For Cancer Research Annual Meeting
    Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma
    Feb 02, 2016: Almac Discovery Secures Patent Protection for Novel allosteric Akt inhibitor (ALM301)
    Jan 28, 2016: ArQule Provides Update on ARQ 092
    Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study
    Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
    Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium
    Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics
    Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology
    Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference
    May 13, 2015: Rexahn Announces Poster Presentation On RX-0201 at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Almac Discovery Ltd, H1 2017
    Pipeline by ArQule Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Bayer AG, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Almac Discovery Ltd
    ArQule Inc
    AstraZeneca Plc
    Bayer AG
    Merck & Co Inc
    Novartis AG
    Rexahn Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//rac-alpha-serine-threonine-protein-kinase-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//rac-alpha-serine-threonine-protein-kinase-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//rac-alpha-serine-threonine-protein-kinase-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments